RESUMEN
El presente estudio se realizó con la finalidad de determinar si la Dipirona altera la agregación plaquetaria. Para ello, se seleccionaron 30 voluntarios sanos, los cuales fueron divididos en dos grupos y asignados al azar a recibir 1 g de Dipirona o 100 mg de Acido Acetilsalicílico. Se determinó la agregación plaquetaria a través del método turbidimétrico; utilizando adenosin difosfato, colágeno y adrenalina. En el grupo Dipirona, se observó una reducción estadísticamente significativa de la agregación plaquetaria a las 72 horas, frente a los 3 estímulos; que revirtió a las 24 horas. En el grupo Acido Acetilsalicílico, disminuyó significativamente la agregación plaquetaria a las 24 horas. Al comparar ambos grupos no hubo diferencia significativa en la muestra basal pero si a las 24 horas. Podemos concluir que la Dipirona, al igual que el resto de los antiinflamatorios no esteroideos, inhibe la agregación plaquetaria de forma reversible, al contrario del Acido Acetilsalicílico.
Asunto(s)
Humanos , Masculino , Adulto , Femenino , Persona de Mediana Edad , Agregación Celular , Aspirina/administración & dosificación , Dipirona/administración & dosificación , PlaquetasRESUMEN
Therapeutic options for developing countries have to assure an optimum safety and efficacy and low-cost antihaemophilic concentrates. A single blind randomized crossover study was carried out in 12 previously treated HB patients, comparing the pharmacokinetics (PK), thrombogenicity (TG) and safety of two plasma-derived double-inactivated (solvent/detergent heating at 100 degrees C, 30 min) factor IX (FIX) concentrates, UMAN COMPLEX DI (product A) [plasma-derived prothrombin concentrates (PCC)] and a high purity FIX concentrate AIMAFIX DI (product B, HPFIX). In a non-bleeding state, they received one single intravenous dose 50 IU FIX kg(-1) of PCC or HPFIX, and after a wash-out period of 14 days, the other product. We evaluated acute tolerance and determined PK parameters based on FIX levels measured over a 50 h postinfusion period. We studied fibrinogen, platelets, antithrombin, F1 + 2, TAT, D-dimer, over a 360 min postinfusion period. Ten cases remained in on-demand treatment for 6 months, five with PCC and five with HPFIX. PK and anti-FIX inhibitors were repeated at 3 and 6 months. No inhibitors were detected. PK values (PCC vs. HPFIX): clearence (CL; mL h(-1) kg(-1)) 5.2 +/- 1.4 vs. 6.5 +/- 1.4; the volume of distribution at steady state (mL kg(-1)) 154.9 +/- 54.9 vs. 197.5 +/- 72.5; mean residence time (h) 29.7 +/- 8.1 vs. 30.7 +/- 9.2; T(1/2) (h) 22.3 +/- 7 vs. 23.5 +/- 12.3; incremental recovery (IR; U dL(-1) U(-1) kg(-1)) 0.96 +/- 0.17 vs. 0.76 +/- 0.13. HPFIX showed significant lower IR and higher CL. There were no differences in PK at 3 and 6 months. In TG, significant increments in TAT and F1 + 2 at 30 min and 6 h were found with PCC. Product B PK results agrees with reported results for other HPFIX preparations. Use of PCC product A has to consider its thrombogenic activity.
Asunto(s)
Factores de Coagulación Sanguínea/administración & dosificación , Factor IX/administración & dosificación , Hemofilia B/tratamiento farmacológico , Adolescente , Adulto , Antitrombina III/análisis , Biomarcadores/sangre , Factores de Coagulación Sanguínea/farmacocinética , Estudios Cruzados , Factor IX/farmacocinética , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Fibrinógeno/análisis , Hemofilia B/sangre , Hemofilia B/fisiopatología , Hemostasis/fisiología , Humanos , Inyecciones Intravenosas , Fragmentos de Péptidos/análisis , Péptido Hidrolasas/sangre , Recuento de Plaquetas/métodos , Protrombina/análisis , Método Simple CiegoRESUMEN
We report a case of ischemic colitis with pseudomembrane formation in a 6 1/2-year-old boy with sickle cell disease that responded to medical management including exchange transfusion. This case was not associated with Clostridium difficile infection but with an elevation of serum levels of tumor necrosis factor alpha. This rare complication of sickle cell disease has been reported only in adults.